Company Overview: CRSP

Upcoming Projects (CRSP)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (CRSP)

DIgging into the Phase 1 Data of CRISPR therapeutics' CTX310 gene therapy for cardiovascular disease.
Ticker: CRSP
Executed On: Jun 16, 2025 at 10:00 AM EDT
Discussing the potential of gene therapies for sickle cell disease including Vertex and CRISPR Therapeutics' Casgevy (Exa-cel) and Bluebird bio's Lyfgenia (lovotibeglogene autotemcel)
Tickers: VRTX, CRSP
Executed On: Mar 13, 2025 at 12:45 PM EDT
A Second Look: Prime editing compared to CRISPR/Cas9 gene editing and its potential in future therapeutics
Tickers: PRME, VRTX, CRSP
Executed On: May 24, 2024 at 03:00 PM EDT
Discussing prime editing compared to CRISPR/Cas9 gene editing and its potential in future therapeutics
Tickers: PRME, VRTX, CRSP
Executed On: May 16, 2024 at 10:00 AM EDT
A look at gene therapies in Sickle Cell disease including Vertex and CRISPR Therapeutics' CASGEVY (Exa-cel) and bluebird bio's LYFGENIA (lovotibeglogene autotemcel).
Tickers: VRTX, BLUE, CRSP
Executed On: Apr 30, 2024 at 01:00 PM EDT
Transforming Beta-Thalassemia Care: A Detailed Exploration of CRISPR Therapeutics AG's CASGEVY and how it compares against other approved products
Ticker: CRSP
Executed On: Apr 23, 2024 at 09:00 AM EDT
A Second View: Revolutionizing Sickle Cell Disease and Thalassemia Treatment: A Deep Dive into the EDIT-301 ASH Clinical Data Abstract and the approval of CASGEVY & Lyfgenia
Tickers: EDIT, BLUE, CRSP, VRTX, BBIO
Executed On: Dec 20, 2023 at 04:00 PM EST
Revolutionizing Sickle Cell Disease and Thalassemia Treatment: A Deep Dive into the EDIT-301 ASH Clinical Data Abstract and the approval of CASGEVY & Lyfgenia
Tickers: EDIT, BLUE, CRSP, VRTX, BBIO
Executed On: Dec 20, 2023 at 01:30 PM EST
An updated look at Vertex & CRISPR's exa-cel in patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: VRTX, CRSP
Executed On: Sep 01, 2023 at 11:30 AM EDT
A Second View: Discussing the potential Vertex & CRISPR's exa-cel in patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: VRTX, CRSP
Executed On: Apr 26, 2023 at 10:30 AM EDT
Reviewing EDIT-301 as an experimental cell therapy medicine for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: EDIT, VRTX, BLUE, CRSP
Executed On: Mar 03, 2023 at 10:00 AM EST
Discussing the potential Vertex & CRISPR's exa-cel in patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: VRTX, CRSP
Executed On: Jan 26, 2023 at 12:00 PM EST
Discussion of current NHL CAR-T and outlook for allogeneic therapies in DLBCL
Tickers: BMY, GILD, NVS, CRSP, ALLO, ACET
Executed On: May 03, 2022 at 01:00 PM EDT

Expired Projects (CRSP)

An in-depth look at the Gene Therapy Landscape
Tickers: VRTX, BLUE, ONCE, CRSP, EDIT, NTLA
Execute By: Dec 31, 2021

Upcoming & Overdue Catalysts (CRSP)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (CRSP)

Between second half 2017 and first half 2018, Intellia Therapeutics (NTLA) will start initial new drug application-based (IND) studies on Transtherytin Amyloidosis (ATTR), a gene-editing therapy using from CRISPR/Cas9 gene revision concept
Tickers: NTLA, CRSP, BAYRY
Occurred on: Oct 18, 2018
Intellia Therapeutics (NTLA) set to commence non-human primate (NHP) studies on Transtherytin Amyloidosis (ATTR), a gene-editing therapy developed with Regeneron based on the CRISPR/Cas9 genetic editing system in 2017
Tickers: NTLA, CRSP, BAYRY, REGN
Occurred on: May 01, 2018
NTLA in vivo Hepatitis B Virus (HBV) program by Intellia, based on CRISPR/Cas9 genetic editing system, set for HBV animal trials in 2017
Tickers: NTLA, BAYRY, CRSP
Occurred on: May 01, 2018
CRISPR (CRSP) Therapeutics preparing to file clinical trial authorization application (CTA) in Europe by end of 2017 for CRISPR/Cas9 gene editing product to treat beta-thalassemia, a disorder causing hemoglobin deficiency
Tickers: CRSP, BAYRY
Occurred on: Dec 07, 2017
CRISPR and Casebia by Bayer (BAYRY) obtain rights to MaxCyte's cell engineering platform to create therapies for hemoglobin disorders and immunodeficiency
Tickers: CRSP, BAYRY
Occurred on: Mar 14, 2017

Strategic Initiatives (CRSP)

Don’t see a strategic initiative related to the company you care about? Create your own!

CRSP Overview